An FDA advisory committee has narrowly recommended allowing US pharmacies to compound six popular peptides, including BPC-157, TB-500 and MOTS-c, against the advice of the FDA’s own scientists. At its meeting on 23–24 July 2026, the Pharmacy Compounding Advisory Committee (PCAC) voted 8–6, with 1 abstention, to recommend BPC-157, KPV and TB-500 for the agency’s 503A Bulks List, and 7–5, with 2 abstentions, for MOTS-c. Semax and epitalon were backed the next day; emideltide (delta sleep-inducing peptide) was the only one rejected. The votes do not change anything yet: the FDA has to decide whether to accept them and then write a rule.
What was voted on
| Peptide | Use the FDA reviewed | Vote |
|---|---|---|
| BPC-157 | Ulcerative colitis | 8–6 (1 abstention) in favor |
| KPV | Wound healing and inflammatory conditions | 8–6 (1 abstention) in favor |
| TB-500 | Wound healing | 8–6 (1 abstention) in favor |
| MOTS-c | Obesity and osteoporosis | 7–5 (2 abstentions) in favor |
| Semax | Cerebral ischemia, migraine, trigeminal neuralgia | Backed by a tight margin (24 July) |
| Epitalon | Insomnia | Backed by a tight margin (24 July) |
| Emideltide (DSIP) | Opioid withdrawal, chronic insomnia, narcolepsy | Rejected 7–6 (1 abstention) |
Why it was controversial
FDA staff had recommended against adding any of the seven substances. Their briefing materials found that the available studies, including the five small human reports on BPC-157, were short, small and insufficient to establish safety or effectiveness for the uses under review. For TB-500, the FDA found no human exposure data at all, and for MOTS-c no completed human trial of the peptide itself. Reports from the meeting described the panel’s votes against the written staff recommendation as highly unusual. The reconstituted panel also drew scrutiny for including more health professionals who prescribe or promote peptides than earlier panels.
What happens next
Nothing changes immediately. The committee’s votes are non-binding. None of the peptides has been added to the 503A Bulks List, and none is an FDA-approved drug. The FDA must decide whether to accept the recommendations and, if it does, go through notice-and-comment rulemaking (a proposed rule, public comments and a final rule) before compounding pharmacies could legally prepare them. As of 30 October 2026, we found no final FDA decision.
What it means for users
- Legal status: unchanged for now. Products sold online as “research peptides” are still not approved drugs.
- Evidence: unchanged. The vote did not add any new data; BPC-157’s human evidence remains five small reports, rated very low certainty in a 2026 systematic review.
- Sport: BPC-157 (S0), TB-500 (S2.3) and MOTS-c (S4.4.1) remain banned by WADA at all times.
For the evidence on each, see the BPC-157 review, BPC-157 vs TB-500 and the database.
Frequently asked questions
Did the FDA approve BPC-157?
NoEvidence: Law
An FDA advisory committee voted 8–6 to recommend allowing pharmacy compounding of BPC-157 for ulcerative colitis. The vote is non-binding, and BPC-157 is not an approved drug.
Can pharmacies compound BPC-157 now?
Not yetEvidence: Law
The FDA must accept the recommendation and complete notice-and-comment rulemaking before BPC-157 can be added to the 503A Bulks List. As of 30 October 2026, no final FDA decision was found.
Which peptides did the panel reject?
Only emideltide (DSIP)Evidence: Law
Emideltide (delta sleep-inducing peptide) was voted down 7–6 with 1 abstention.
Why did FDA staff oppose the peptides?
Too little evidenceEvidence: Law
Their review found the available studies short, small and insufficient to establish safety or effectiveness. TB-500 had no human exposure data at all.
Sources
- FDA: July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee (agenda)
- AJMC: FDA Panel Backs 6 Peptides for Compounding (31 July 2026)
- RAPS: FDA advisory committee backs two controversial peptides (23 July 2026)
- FDA Briefing Document, Pharmacy Compounding Advisory Committee, 23-24 July 2026: BPC-157-related bulk drug substances
- FDA Briefing Document, Pharmacy Compounding Advisory Committee, 23-24 July 2026: TB-500-related bulk drug substances
- FDA Briefing Document, Pharmacy Compounding Advisory Committee, 23-24 July 2026: MOTS-c-related bulk drug substances
- Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety
- World Anti-Doping Code International Standard: Prohibited List 2026